BioVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioVie Inc. on December 23, 2022. The report details an update regarding the Company's Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc.
Key Financial Metrics
- Capital Raised: As of December 20, 2022, the Company issued 3,709,509 shares under the Sales Agreement.
- Net Proceeds: Total net proceeds amounted to $29.0 million.
- Expenses: Commissions and expenses totaled approximately $898,000.
- Offering Capacity: The Sales Agreement allows for the sale of shares with an aggregate offering price of up to $17.5 million (note: proceeds to date exceed this specific supplement limit, indicating prior activity under the agreement).
Material Changes
The filing reports the issuance of a prospectus supplement on December 23, 2022, in connection with the ongoing equity offering. The primary material change is the accumulation of $29.0 million in net proceeds from the sale of 3,709,509 shares as of December 20, 2022.
Outlook and Risks
The Company continues to offer and sell shares from time to time through the designated sales agents pursuant to the effective registration statement on Form S-3. The filing explicitly states it does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful without registration.
Investor Verification Checklist
- Verify the current share count and dilution impact of the 3,709,509 shares issued.
- Confirm the remaining capacity available under the $17.5 million aggregate offering price limit mentioned in the supplement versus the $29.0 million already raised.
- Review the use of proceeds for the $29.0 million net capital raised.
- Check for any subsequent 8-K filings regarding further sales under the Sales Agreement.